Brugada syndrome (BrS) is a genetic arrhythmia disorder that predisposes affected individuals to sudden cardiac death. There are currently greater than 20 genes reported to cause BrS and found on clinical genetic testing panels.
The goal of the BrS GC-EP is to evaluate the clinical validity of these gene-disease associations in order to optimize care and clinical decision making for patients and families diagnosed with this disorder.
|Michael Gollob, MD||Executive Leadership|
|Ray Hershberger, MD||Executive Committee|
|Michael Ackerman, MD PhD||Executive Committee|
|Arthur Wilde MD, PhD||Executive Committee|
|C. Lisa Kurtz, PhD||Coordinator|
|Melanie Care, MSc, CGC||Member|
|John Garcia, PhD||Member|
|Jenny Goldstein, PhD, CGC||Member|
|Valeria Novelli PhD||Member|
|Amy Sturm, MS, LGC||Member|
|James Ware, PhD||Member|
Please contact a coordinator if you have questions.
A systematic process of evaluating the strength of evidence supporting or refuting a claim that variation in a particular gene causes a particular disease.